/stocks — the workspaceLOADING
All SPTXSEC filings, by type → · Earnings date & implied move · Search inside filings
Seaport Therapeutics, Inc. (SPTX) is a pharmaceutical preparations company. 1 insider Form 4 filings in the last 90 days. Fundamentals from SEC filings; prices are end-of-day.
What’s behind SPTX’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Not reported in XBRL for this filer.
A plain-English read on SPTX plus an auto-SWOT — built from SPTX's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate SPTX using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
Has SPTX been issuing shares? Offering history →
No lawmaker has disclosed a trade in SPTX under the STOCK Act.
No tracked institution reported a position in SPTX in the latest 13F round.
Projected from SPTX's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentSPTX files or announces.
| Reported | Close-to-close |
|---|---|
| 2026-08-03 | +4.7% |
| 2026-06-08 | +7.4% |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| HOMBACH ROBERT J.Director | BUY | $236K | view → |
| ARCH Venture Partners XII, LLC10% owner | BUY | $19.8M | view → |
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.